Radionuclides and carrier molecules for therapy

Physics in Medicine and Biology

Volumn 41, Issue 10, 1996, Pages 1905-1914

  Zweit, Jamal ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATE; RADIOISOTOPE; SODIUM IODIDE I 131;

ARTICLE; CANCER THERAPY; PRIORITY JOURNAL; RADIATION DOSE; TUMOR LOCALIZATION;

HUMANS; NEOPLASMS; POLYCYTHEMIA VERA; RADIOISOTOPES; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 0029768882     PISSN: 00319155     EISSN: None     Source Type: Journal    
DOI: 10.1088/0031-9155/41/10/004     Document Type: Article

References (40)

1. Adelstein S J and Kassis A I 1987 Radiobiologic implications of the microscopic distribution of energy from radionuclides Nucl. Med. Biol. 14 165-9
2. 131I therapy and total body irradiation for treatment of disseminated tumours of differing radiosensitivity Int. J. Radiat. Oncol. Biol. Phys. 27 323-30
3. 67Cu Int. J. Radiat. Biol. 55 365-84
4. 224Ra Appl. Radiat. Isot. 39 283-6
5. Baranowska-Kortylewicz J B, Helseth L D, Lai J, Schneiderman M H, Schneiderman G S and Dalrymple G V 1994 Radiolabelling kit/generator for 5-radiohalogenated uridines J. Lab. Comps. Radiopharm. 34 513-21
6. Bigler R E and Zanzonico P B 1988 Adjuvant radioimmunotherapy for micrometastases Radiolabelled Monoclonal Antibodies for Imaging and Therapy ed S C Srivastava (New York: Plenum) pp 409-28
7. Brown I, Carpenter R N, Link E and Mitchell J S 1986 Potential diagnostic and therapeutic agents for malignant melanoma: synthesis of heavy radiohalogenated derivatives of methylene blue by electrophilic and nucleophilic methods J. Radioanal. Nucl. Chem. Lett. 107 337-51
8. Cole A 1969 Absorption of 20 eV to 50,000 eV electron beams in air and plastic Radiat. Res. 38 7-33
9. de Klerk J M H, Zonnenberg B A, van het Schip A D, van Dijk A, Han S H, Quirijnen J M S P, Blijham G H and van Rijk P P 1994 Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer Eur. J. Nucl. Med. 21 1114-20
10. Emran A M and Phillips D R 1991 Biomedical use of arsenic radioisotopes New Trends in Radiopharmaceutical Synthesis, Quality Assurance and Regulatory Control ed A M Emran (New York: Plenum) pp 153-68
11. Farhanghi M, Holmes R A, Volkert W A, Logan K W and Singh A 1992 Samarium-153-EDTMP: pharmacokinetics, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer J. Nucl. Med. 33 1451-8
12. Geerlings M W, Kaspersen F M, Apostolidis C and Van Der Hout R 1993 The feasibility of 225Ac as a source of α-particles in radioimmunotherapy Nucl. Med. Commun. 14 121-5
13. Grazman B and Troutner D E 1988 Rhodium-105 as a potential radiotherapeutic agent Appl. Radiat. Isotopes 39 257-60
14. Hassfjell S P, Hoff P, Bruland O S and Alstad J 1994 212PB/212Bi-EDTMP - synthesis and biodistribution of a novel bone seeking alpha-emitting radpharmaceutical J. Lab. Comps. Radiopharm. 34 717-33
15. Hoefnagel C A 1991 Radionuclide therapy revisited Eur. J. Nucl. Med. 18 408-31
16. Howell R W, Kassis A I, Adelstein S J, Rao D V, Wright H A, Hamm R N, Turner J E and Sastry K S R 1994 Radiotoxicity of platinum-195m-labelled trans-platinum (II) in mammalian cells Radiat. Res. 140 55-62
17. Howell R W, Rao D V and Sastry K S 1989 Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumours Med. Phys. 16 66-74
18. Humm J L 1986 Dosimetric aspects of radiolabelled antibodies for tumour therapy. J. Nucl. Med. 27 1490-7
19. Humm J L and Cobb L M 1990 Nonuniformity of tumour dose in radioimmunotherapy J. Nucl. Med. 31 75-83
20. 105Rh Appl. Radiat. Isotopes 40 701-5
21. Kozak R W, Atcher R W, Gansow C A, Friedman A M, Hines J J and Waldmann T A 1986 Bismuth-212-labelled anti-TAC monoclonal antibody: alpha-particle emitting radionuclides as modalities for radioimmunotherapy Proc. Natl Acad. Sci. USA 83 474-8
22. Lederer C M and Shirley V S (eds) 1978 Table of Isotopes 7th edn (New York: Wiley)
23. Link E M and Carpenter R N 1992 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumours and lymph node metastases Cancer Res. 52 4385-90
24. Macklis R M, Kinsey B M, Kassis A I, Ferrara J L M, Atcher R W, Hines J J, Coleman C N, Adelstein S J and Burakoff S J 1988 Radioimmunotherapy with alpha-particle-emitting immunoconjugates Science 240 1024-6
25. O'Donoghue J A, Bardies M and Wheldon T E 1995 Relationship between tumour size and curability for uniformly targeted therapy with beta-emitting radionuclides J. Nucl. Med. 36 1902-9
26. O'Donoghue J A and Wheldon T E 1996 Targeted therapy using Auger-electron emitters Phys. Med. Biol. 41 1973-92
27. Ott R J 1996 Imaging technologies for radionuclide dosimetry Phys. Med. Biol. 41 1885-94
28. Palayoor S T, Humm J L, Atcher R W, Hines J J and Macklis R M 1993 G2M arrest and apoptosis in murine T lymphoma cells following exposure to 212Bi alpha particle irradiation Nucl. Med. Biol. 20 795-805
29. Pillai M R A, John C S and Trounter D E 1990 Labelling of human IgG with 105Rh using a new pentadentate bifunctional ligand Bioconj. Chem. 2 191-7
30. Sastry K S R 1992 Biological effects of the Auger emitter iodine-125: a review. Report No 1 of AAPM Nuclear Medicine Task Group No 6 Med. Phys. 19 1361-83
31. Sowby F D (ed) 1983 Radionuclide Transformations, Energy and Intensity of Emissions (New York: Pergamon)
32. Turkington T G, Zalutsky M R, Jaszczak R J, Garg P K, Vaidyanathan G and Coleman R E 1993 Measuring astatine-211 distributions with SPECT Phys. Med. Biol. 38 1121-30
33. Vaidyanathan G and Zalutsky M R 1992 1-(m-[211At] astatobenzyl) guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation Bioconj. Chem. 3 499-503
34. _1996 Targeted therapy using alpha emitters Phys. Med. Biol. 41 1915-31
35. Volkert W A, Goeckeler W F, Ehrhardt G J and Ketring A R 1991 Therapeutic radionuclides: production and decay property consideration J. Nucl. Med. 32 174-85
36. Wessels B W and Rogus R D 1984 Radionuclide selection and model absorbed dose calculations for radiolabelled tumour associated antibodies Med. Phys. 11 638-45
37. Wheldon T E (ed) 1988 Mathematical Models in Cancer Research (Bristol: Adam Higler) pp 203-24
38. Zalutsky M R, Garg P K, Friedman H S and Bigner D D 1989 Labelling monoclonal antibodies and F(ab′)2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity Proc. Natl Acad. Sci. USA 86 7149-53
39. Zalutsky M R and Narula A 1988 Astatination of proteins using an N-succinimidyl tri-nbutylstannyl benzoate intermediate Appl. Radiat. Isotopes 39 227-32
40. Zweit J 1989 The production of medium half-life radionuclides for positron emission tomography PhD Thesis University of Manchester